Irinotecan Fails to Boost Rectal Cancer Outcomes

Published Date: 12 Aug 2026

Adding irinotecan to standard chemoradiotherapy for MRI-defined, locally advanced rectal cancer did not improve disease-free survival or pathologic complete response rates but increased toxicity, including diarrhea and neutropenia.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot